Allergan Aesthetics Files sNDA for BOTOX Cosmetic Jawline Indication with FDA

Allergan Aesthetics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of BOTOX Cosmetic for a jawline contouring indication, advancing one of the more closely watched label expansion efforts in the aesthetics biologics space. For regulatory affairs leads tracking aesthetic indication pathways, the submission signals how established botulinum toxin franchises are being extended through incremental clinical programs rather than new molecular entities.

The sNDA route is the standard mechanism for adding indications to an approved biologic or drug product, requiring the applicant to demonstrate safety and efficacy for the new use while leveraging the existing approval infrastructure. Allergan's filing draws on the existing BOTOX Cosmetic regulatory dossier, meaning the CMC package, manufacturing controls, and sterility assurance data already on file with the agency underpin the new submission. QA and regulatory teams at contract manufacturers holding BOTOX fill-finish agreements should anticipate no immediate change to batch release or labeling workflows until a decision is issued.

Label expansions of this type carry a defined review clock under 21 CFR Part 314 for standard applications, typically ten months from filing date, though priority designations can compress that timeline. The jawline indication would represent the first new facial aesthetic approval for BOTOX Cosmetic in several years, and the outcome will be read by competitors navigating similar aesthetic indication strategies for their own neurotoxin portfolios.

From a post-market surveillance standpoint, an approved jawline indication would require updated prescriber labeling, revised patient medication guides, and potentially new REMS considerations depending on FDA's benefit-risk assessment for the anatomical site. QA directors at specialty distribution partners should begin mapping those downstream documentation requirements now rather than at approval.

The FDA's action date, once formally assigned, will mark the next measurable checkpoint for this program.

Source: Media4Growth via Indian Pharma Post, 5 August 2026.